Concepedia

Publication | Closed Access

Phase II, Open-Label Study of Brivanib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma

DOI

142

Citations

21

References

2011

Year

Joong‐Won Park, Richard S. Finn, Jun Suk Kim, Mark Karwal, Ruby K. Li, Fuad Ismail, Melanie B. Thomas, Rosemarie Harris, Christine Baudelet, Ian Walters,
Clinical Cancer Research

Abstract

Brivanib as first-line therapy demonstrates promising antitumor activity and a manageable safety profile in patients with advanced, unresectable HCC.

References

YearCitations

Page 1